Add an SSRI as First-Line Treatment
For a patient with PMDD already on combined oral contraceptives, add a selective serotonin reuptake inhibitor (SSRI) as the next step in management. The evidence clearly demonstrates that SSRIs are the most effective first-line pharmacologic treatment for PMDD, even when patients are already using hormonal contraception 1, 2.
Treatment Algorithm
Step 1: Initiate SSRI Therapy
Start one of the following SSRIs at these specific doses 2:
- Sertraline 50-150 mg/day
- Fluoxetine 10-20 mg/day
- Escitalopram 10-20 mg/day
- Paroxetine 12.5-25 mg/day
The most recent network meta-analysis found that continuous paroxetine showed the greatest effect across all PMDD symptom domains 3, making it a particularly strong choice if there are no contraindications.
Step 2: Consider Dosing Strategy
You can administer SSRIs either:
- Continuously (daily) - simpler for adherence
- Luteal phase only (14 days before expected menses) - may reduce side effects
Both strategies are effective for PMDD 1.
Step 3: Optimize the Current COC Regimen
If the patient is on a traditional 21/7 COC regimen, consider switching to:
- Drospirenone 3mg/ethinyl estradiol 20mcg in a 24/4 regimen (24 days active pills, 4 days inactive)
This specific formulation and dosing schedule was identified as the most effective COC for PMDD, particularly for physical and emotional symptoms 3. The 24/4 regimen reduces hormone-free intervals that can trigger symptoms 4.
Important Evidence Considerations
The SSRI recommendation is based on the strongest evidence. The 2023 ACOG guideline explicitly identifies SSRIs as evidence-based treatment for premenstrual disorders 1, and multiple sources confirm their first-line status 2. A 2026 network meta-analysis reinforces that continuous paroxetine demonstrates superior efficacy 3.
Regarding COCs alone: While drospirenone-containing COCs show benefit over placebo 4, one high-quality RCT found that both continuous and intermittent dosing of drospirenone/EE showed similar improvements to placebo, with a marked placebo response 5. This suggests that if the patient is already on a COC without adequate symptom control, simply continuing or switching COCs may not be sufficient.
Common Pitfalls to Avoid
- Don't assume the current COC is optimized - many patients are on traditional 21/7 regimens rather than the more effective 24/4 drospirenone formulation
- Don't delay SSRI initiation - waiting to "try other things first" prolongs suffering when SSRIs have the strongest evidence base
- Don't confuse PMS with PMDD - ensure diagnosis is confirmed with prospective symptom charting over 2 menstrual cycles 1
Additional Considerations
If SSRIs are contraindicated or not tolerated, consider:
- Cognitive Behavioral Therapy (CBT) - shows effectiveness in reducing functional impairment, mood symptoms, and symptom severity 2
- Alternative COC formulation - nomegestrol acetate/17-beta estradiol shows preliminary promise with 74.5% reporting positive mood response 6
The combination of SSRI plus optimized COC addresses both the serotonergic dysregulation and hormonal fluctuations implicated in PMDD pathophysiology 2.